Trial 6G-15-3


Study of Immunotherapy in Newly Diagnosed Glioblastoma: A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Biological Response Modifier, Chemotherapy: Systemic, Radiation: External, Vaccine
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Naveed Wagle, M.D.
Other Trial Staff:  Aida Lozada, D.M., Aida Lozada, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.